overall survival – Page 2

$Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial$

Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial

By MedXY 08/07/2025

Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.

$Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights$

Clinical Updates Hematology-Oncology news Specialties

Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights

By MedXY 08/02/2025

The DREAMM-7 trial demonstrates that belantamab mafodotin with bortezomib and dexamethasone significantly improves survival in relapsed/refractory multiple myeloma, suggesting a new standard of care.

Clinical Updates news Oncology Specialties

Inavolisib Improves Overall Survival in PIK3CA-Mutated Advanced Breast Cancer: Results from the INAVO120 Study

By MedXY 08/01/2025

Inavolisib combined with palbociclib and fulvestrant significantly prolongs overall survival in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, but increases certain toxicities.

Clinical Updates Hematology-Oncology news Specialties

Ivosidenib Plus Azacitidine Significantly Improves Survival in IDH1-Mutated AML: Long-Term Results from the AGILE Study

By MedXY 07/31/2025

The AGILE trial shows ivosidenib plus azacitidine more than triples median overall survival in newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy, with improved hematologic recovery and safety.